Abstract: A method of treating chronic active ulcerative colitis in a subject that is refractory or responds insufficiently or is intolerant to anti-inflammatory therapy, comprises administering to a patient in need thereof an effective exposure of an oligonucleotide comprising the sequence 5?-GGAACAGTTCGTCCATGGC-3? (SEQ ID NO.2), wherein at least one CG dinucleotide is unmethylated. The oligonucleotide is not administered with corticosteroids or glucocorticosteroids.

Abstract: A method of treating chronic active ulcerative colitis in a subject that is refractory or responds insufficiently or is intolerant to anti-inflammatory therapy, comprises administering to a patient in need thereof an effective exposure of an oligonucleotide comprising the sequence 5?-GGAACAGTTCGTCCATGGC-3? (SEQ ID NO.2), wherein at least one CG dinucleotide is unmethylated. The oligonucleotide is not administered with corticosteroids or glucocorticosteroids.

Abstract: The present invention relates to methods of identifying oligonucleotides capable of modulating the immune system in a mammalian subject, comprising analysis of which tertiary structural type said oligonucleotide adopts, in phosphate-buffered saline solution. Further, the invention provides oligonucleotides identifiable by the methods of the invention and to their use in methods of treating diseases, such as inflammatory diseases, autoimmune diseases, infectious diseases, neurodegenerative diseases and cancer.

Abstract: A method of treating chronic active ulcerative colitis in a subject that is refractory or responds insufficiently or is intolerant to anti-inflammatory therapy, comprises administering to a patient in need thereof an effective exposure of an oligonucleotide comprising the sequence 5?-GGAACAGTTCGTCCATGGC-3? (SEQ ID NO.2), wherein at least one CG dinucleotide is unmethylated. The oligonucleotide is not administered with corticosteroids or glucocorticosteroids.

Abstract: The present invention relates to methods of preventing or reducing the need of colectomy. In particular, the present invention relates to an oligonucleotide, for use in the treatment of an inflammatory bowel disease, such as ulcerative colitis (UC) or Crohn's disease, in a subject that is refractory or responds insufficiently or is intolerant to anti-inflammatory therapy, wherein said oligonucleotide is repetitively administered as a single exposure.

Abstract: The present invention relates to methods of identifying oligonucleotides capable of modulating the immune system in a mammalian subject, comprising analysis of which tertiary structural type said oligonucleotide adopts, in phosphate-buffered saline solution. Further, the invention provides oligonucleotides identifiable by the methods of the invention and to their use in methods of treating diseases, such as inflammatory diseases, autoimmune diseases, infectious diseases, neurodegenerative diseases and cancer.

Abstract: The present invention relates to methods of identifying oligonucleotides capable of modulating the immune system in a mammalian subject, comprising analysis of which tertiary structural type said oligonucleotide adopts, in phosphate-buffered saline solution. Further, the invention provides oligonucleotides identifiable by the methods of the invention and to their use in methods of treating diseases, such as inflammatory diseases, autoimmune diseases, infectious diseases, neurodegenerative diseases and cancer.

Abstract: A test kit for selecting a therapy for a steroid resistant patient presenting inflammatory symptoms comprises primer pairs or antibodies specific for at least one marker gene or protein translated from at least one marker gene, and instructions for use. The primer pairs or antibodies enable analysis of expression level of the at least one marker gene or translated protein from the at least one marker gene.

Abstract: The invention concerns an in vitro method for selecting the therapy for a steroid resistant patient, wherein the method comprises isolating cells from a sample taken from said patient; cultivating said isolated cells in the presence of a steroid, an immunomodulatory oligonucleotide or a mixture thereof; determining an expression level of at least one marker gene in said isolated cells; and comparing said expression level of said at least one marker gene to a value obtained from the cultivation of cells from a healthy person in the presence of a steroid, an immunomodulatory oligonucleotide or a mixture thereof, or to a normalized value obtained from a healthy population. Examples of marker genes are CD163, Tsp1, IL1-R2, TLR2, TLR4, MKP-1 and TXK.

Abstract: The present invention relates to methods of identifying oligonucleotides capable of modulating the immune system in a mammalian subject, comprising analysis of which tertiary structural type said oligonucleotide adopts, in phosphate-buffered saline solution. Further, the invention provides oligonucleotides identifiable by the methods of the invention and to their use in methods of treating diseases, such as inflammatory diseases, autoimmune diseases, infectious diseases, neurodegenerative diseases and cancer.

Abstract: The response of immunotherapy in the treatment of cancer is enhanced by use of an oligonucleotide in a dose effective to induce at least one of endogenous production of cytokines, and the regulation of the expression of one or more of the cell surface antigens (FIG. 1).

Abstract: Specific oligonucleotide sequences, when given subcutaneously and in particular when administered on a mucous membrane, e.g. intranasally, intravaginally, or rectally, have a profound effect on various human cancer forms as confirmed in vivo, in animal studies, and in vitro, in human PBMCs collected from blood from healthy subjects and from patients suffering from CLL. The compounds are also preferably used in combination with a cancer therapy chosen among radiation treatment, hormone treatment, surgical intervention, chemotherapy, immunological therapies, photodynamic therapy, laser therapy, hyperthermia, cryotherapy, angiogenesis inhibition, or a combination of any of these, and most preferably an immunological treatment comprising the administration of an antibody to the patient.

Abstract: A quantification of the expression levels of a number of specific genes and their corresponding proteins can be utilized in accurately determining, using samples from faeces or blood, whether the patient is suffering from irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD), and in a follow up analysis using a biopsy, determine if the same patient is afflicted with ulcerative colitis (UC) or Crohn's disease (CD). The method also has utility in determining the severity of the disease, as well as observing a patient's response to treatment.

Abstract: The invention concerns an in vitro method for selecting the therapy for a steroid resistant patient, wherein the method comprises isolating cells from a sample taken from said patient; cultivating said isolated cells in the presence of a steroid, an immunomodulatory oligonucleotide or a mixture thereof; determining an expression level of at least one marker gene in said isolated cells; and comparing said expression level of said at least one marker gene to a value obtained from the cultivation of cells from a healthy person in the presence of a steroid, an immunomodulatory oligonucleotide or a mixture thereof, or to a normalized value obtained from a healthy population. Examples of marker genes are CD163, Tsp1, IL1-R2, TLR2, TLR4, MKP-1 and TXK.

Abstract: Agents useful for modulating the dioxin/aryl hydrocarbon receptor (AhR) can now be identified by determining the binding to said receptor and whether said agent suppresses or inhibits the expression of a gene substantially consisting of a sequence according to one of SEQ. ID. NO. 1 and SEQ. ID. NO. 2; a nucleotide sequence functionally homologous, or substantially homologous, or at least 90% identical to one of SEQ. ID. NO. 1 and SEQ. ID. NO. 2; and a nucleotide sequence complementary to the nucleotide sequence of SEQ. ID. NO. 1 or SEQ. ID. NO. 2. Such agents find utility in pharmaceutical compositions and methods for the prevention, alleviation or treatment of diseases involving gastrointestinal hyperplasia, such as gastrointestinal cancer or gastric cancer.

Abstract: The differentiation between ulcerative colitis and Crohn's disease is made possible by a multi-gene approach where gene expression profiles in biopsy samples obtained from inflamed, and optionally also non-inflamed, areas in the intestines of a patient are studied.

Abstract: The differentiation between ulcerative colitis and Crohn's disease is made possible by a multi-gene approach where gene expression profiles in biopsy samples obtained from inflamed, and optionally also non-inflamed, areas in the intestines of a patient are studied.

Abstract: Agents useful for modulating the dioxin/aryl hydrocarbon receptor (AhR) can now be identified by determining the binding to said receptor and whether said agent suppresses or inhibits the expression of a gene substantially consisting of a sequence according to one of SEQ.ID. NO. 1 and SEQ.ID. NO. 2; a nucleotide sequence functionally homologous, or substantially homologous, or at least 90% identical to one of SEQ.ID. NO. 1 and SEQ.ID. NO. 2; and a nucleotide sequence complementary to the nucleotide sequence of SEQ.ID. NO. 1 or SEQ.ID. NO. 2. Such agents find utility in pharmaceutical compositions and methods for the prevention, alleviation or treatment of diseases involving gastrointestinal hyperplasia, such as gastrointestinal cancer or gastric cancer.

Abstract: The differentiation between ulcerative colitis and Crohn's disease is made possible by a multi-gene approach where gene expression profiles in biopsy samples obtained from inflamed, and optionally also non-inflamed, areas in the intestines of a patient are studied.

Abstract: The present invention relates antisense oligonucleotide compounds for use in modulating the function of nucleic acid molecules encoding neutrophil gelatinase associated lipocalin (NGAL). More specifically, the invention provides compounds of 8 to 50 nucleobases in length capable of specifically hybridising with nucleic acid molecules encoding NGAL and thereby inhibiting the expression of the NGAL protein product, as well as pharmaceutical compositions thereof and methods of their use.